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Objectives: Recently, valvular regurgitation has been observed in patients who have
taken fenfluramine or dexfenfluramine with or without phentermine. This study
describes the clinical, echocardiographic, and pathologic findings of anorexigen-
associated valvular heart disease and the surgical interventions required to treat it.
Methods: We reviewed clinical information on 14 patients with severe anorexigen-
associated valvular disease who underwent cardiac operations.
Results: Thirteen women (mean age 44.2 ± 5.3 years) received fenfluramine, 58.5
± 22.3 mg/day, and phentermine, 32.1 ± 11.4 mg/day, for an average of 12.1 ± 7.3
months before presentation. One woman received dexfenfluramine, 30 mg/day for
13 months, and phentermine, 60 mg/day, concomitantly for 6 months. Presenting
symptoms included dyspnea (12 cases), palpitations (3), and atypical chest pain (3).
Six patients had heart failure, and 4 had a new murmur. Echocardiography demon-
strated severe mitral valve regurgitation in all patients. Seven also had aortic regur-
gitation, and 4 had significant tricuspid regurgitation. Four patients had successful
mitral valve repair, 1 with concomitant aortic valve repair. Ten additional patients
eventually required mitral valve replacement, 5 with concomitant aortic valve
replacement. Excised valves demonstrated a glistening white appearance with
plaque-like encasement of leaflets and chordae. Focal surface proliferation and
fibrosis with a “stuck-on” appearance was consistently found.
Conclusions: Anorexigen use may lead to severe multivalvular regurgitation with
characteristic echocardiographic and pathologic findings. Recognition of drug-
induced valvulopathy is important because of widespread use of these medications
and the uncertain natural history of the disease. Early surgical experience suggests
that valve repair is possible in these young patients.
Obesity is a medical problem in the United States that affects 58million people. Despite the estimated 33 billion dollars spent eachyear by consumers in the United States on diet products and pro-grams,1 the incidence of obesity rose from 25% in 1980 to 33% in1991.2 Obesity contributes directly to increases in related healthcomplications, such as adult-onset diabetes,3 heart disease, and
hypertension, with estimated medical costs of nearly 40 billion dollars a year.4
Many weight-loss methods are ineffective, but in prospective trials, prescrip-
tion anorectics such as fenfluramine and phentermine (Figure 1) produced sig-
nificantly greater weight loss than did placebo medications.5 The combined use
of fenfluramine and phentermine was proposed in 1984 by Weintraub and asso-
ciates.6 Dexfenfluramine, the D-isomer of fenfluramine, was approved for use in
the United States in April 1996, and in that same year, more than 18 million
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monthly prescriptions were written in this country for the
three popular anorexigens fenfluramine, dexfenfluramine,
and phentermine.7
In July 1997, a report called attention to a possible asso-
ciation, in 24 patients, between a unique type of valvular
heart disease and the use of diet medications.8 By
September 1997, more than 100 cases of anorexigen-associ-
ated valvular disease had been reported to the Food and
Drug Administration (FDA), including those of 21 patients
who required cardiac surgery for treatment of their disease.
The pathophysiologic mechanism and the natural history of
anorexigen-associated valvular disease remain unknown. To
define common characteristics among patients with this dis-
ease and to suggest a plan for management of patients
requiring surgical intervention, we report this review of 14
of the 21 known surgical patients.
Methods
Between May 1996 and April 1997, valvular heart disease was
identified in 24 women who had taken the drug combination fen-
fluramine and phentermine.8 In this group, 5 patients required
repair or replacement of diseased heart valves. After this initial
description, other cases of valvular disease were reported to our
institution from physicians nationwide, and a database was estab-
lished to document identified cases. From a database of 175
patients with suspected anorexigen-associated valvular disease, we
found a total of 14 patients (including the original 5) who had car-
diac surgery for treatment of severe valvular heart disease; these
patients had operations at 9 different institutions. All available
diagnostic test reports and patient records were reviewed. In cases
missing specific data, patients were contacted directly.
Results
The characteristics of the 14 women (mean age 44.2 ± 5.3
years) and their evaluations, treatments, and findings are
presented in Tables 1 and 2. Preoperatively, 13 women were
prescribed fenfluramine (mean dosage 58.5 ± 22.3 mg/day)
and phentermine (32.1 ± 11.4 mg/day) for an average dura-
tion of 12.1 ± 7.3 months. One woman received dexfenflur-
amine (30 mg/day) for 13 months with phentermine (60
mg/day) concomitantly for 6 months. The average body
mass index (weight in kilograms/height in meters squared)
of the surgical patients before initiation of diet drug therapy
was 31.6 ± 4.7 kg/m2.
Before they began taking diet drugs, 13 of the 14 women
had no history of cardiac disease and had normal cardiac
findings as part of their general physical examinations. One
patient had scarlet fever as a child but with no known car-
diac complications and with normal cardiac examinations as
an adult. None of the patients had echocardiograms docu-
menting the absence of valvular heart disease before initia-
tion of anorexigen therapy. After diet drug usage, however,
all 14 patients had severe valvular disease that could not be
attributed to any other cause. The most common symptom,
for which 12 patients (85%) saw a physician, was dyspnea.
Three patients reported palpitations (21%), and 3 described
atypical chest pain. At presentation, 7 patients were noted to
be in congestive heart failure on the basis of physical exam-
ination and chest x-ray films. In addition, 4 patients had a
new, prominent murmur that was identified on their initial
physical examination.
Preoperative echocardiography demonstrated severe
mitral valve regurgitation in all patients, and 7 (50%)
patients also had severe aortic valve regurgitation; 4 had
moderate or greater tricuspid valve regurgitation. The char-
acteristic echocardiographic findings included thickened
valve leaflets tethered by shortened and thickened chordae.8
The valve structure noted by echocardiography was similar
to features of chronic rheumatic involvement but without
Figure 1. Structures of amphetamine, fenfluramine, and phentermine.
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TABLE I. Patient characteristics
Demographics Medical history
Case Age (y) Sex Weight (kg) Height (cm) BMI (kg/m2) Other medications
1 48 F 85 157 34.5 Sertraline, hydrochlorothiazide
2 44 F 91 160 35.5 Lisinopril, conjugated estrogens, 
theophylline
3 50 F 96 158 38.5 Nortriptyline, propylthiouracil
4 41 F 108 165 39.7 None
5 52 F 69 158 27.6 Fluoxetine
6 40 F 82 167 29.0 None
7 44 F 89 168 31.7 Ranitidine
8 41 F 71 152 30.7 None
9 51 F 80 158 32.2 Conjugated estrogens
10 44 F 88 160 34.3 Pirbuterol acetate, triamcinolone
11 37 F 74 163 28.0 None
12 46 F 84 162 32.0 Enalapril, lansoprazole, sulfacetamide
13 34 F 63 165 23.5 Prednisone 
14 47 F 68 163 25.6 Lisinopril, furosemide, zolpidem
Mean ± SD 44.2 ± 5.3 82.0 ± 12.3 161.1 ± 4.4 31.6 ± 4.7
BMI, Body mass index; SD, standard deviation
TABLE 2. Summary of evaluations, treatments, and findings
Case Presentation Echocardiography Catheterization
1 Dyspnea, edema Severe MR, moderate AR Severe MR, normal coronaries, 
PAP 35/16 mm Hg
2 CHF, dyspnea, murmur Severe AR and MR, moderate TR, EF 40% Severe AR and MR, PAP 55/31 mm Hg
3 Dyspnea Severe MR, RVSP 52 mm Hg Moderate MR, EF 50%
4 Dyspnea, murmur Severe MR, thickened MV Severe MR, normal coronaries
5 CHF, murmur, dyspnea Severe MR, RVSP 75 mm Hg Normal coronaries
6 Murmur, chest pain, Severe MR, thickened ant. and post. MV leaflets, Normal coronaries, severe MR,
palpitations ruptured chordae, dilated LA, EF = 70% PCWP 58 mm Hg
7 Dyspnea, chest pain Moderate MR, AR, valves structurally normal,  Severe MR, AR, normal coronaries,
chamber dimensions normal EF 70%, PAP 70/18 mm Hg 
8 Dyspnea, CHF Severe MR, AR, thickened MV leaflets, fixed  Normal coronaries, severe MR
post. leaflet; PAP 64 mm Hg
9 Dyspnea, CHF Severe MR, moderate AR AR and MR, normal coronaries, 
normal LV function
10 Dyspnea, chest pain, CHF Severe MR, mild-moderate TR, AR Severe MR; mild TR, AR, normal 
LV function, ostial RCA lesion, 
PAP 39/15 mm Hg
11 Edema Severe MR, thickened leaflets Normal coronaries
12 Hemoptysis, palpitations Severe MR , thickening of both mitral leaflets with Normal coronaries, severe MR, 
tethering  of posterior, dilated LV, PAP 31 mm Hg, EF 60% PAP 60/40 mm Hg
13 Dyspnea, palpitations Severe MR Severe MR, normal LV function, 
normal coronaries
14 Dyspnea, CHF Severe MR, TR; mild AR, thickened mitral, aortic, Normal coronaries
tricuspid leaflets, tethering of post. mitral leaflet, 
dilated LV, EF 57%, PAP 41 mm Hg
CHF, Congestive heart failure; MR, mitral regurgitation; AR, aortic regurgitation; TR, tricuspid regurgitation; EF, left ventricular ejection fraction;
RVSP, right ventricular systolic pressure; MV, mitral valve; ant., anterior; post., posterior; LA, left atrium; PAP, pulmonary artery pressure; LV, left
ventricle; PCWP, pulmonary capillary wedge pressure; RCA, right coronary artery; MVR, mitral valve replacement; AVR, aortic valve replacement;
TV, tricuspid valve; AV, aortic valve; NA, not available.
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Medical history Appetite suppressant use
Results of previous cardiac examination Phentermine (mg/d) Fenfluramine (mg/d) Duration (mo)
Normal 30 60 9
Normal 30 60 12
Normal 30 60 11
Normal 48 120 25
Normal 15 40 12
Normal 30 60 24
Normal 15 60 3
Normal 37 20 6
Normal 34 40 6
Normal 30 60 5
Normal 30 60 12
Normal (scarlet fever at 1 y), all cardiac exams normal 30 60 7
Normal 30 60 24
Normal 60 Dexfenfluramine 30 13 Dex, 6 Phen
32.1 ± 11.4 58.5 ± 22.3  12.4 ± 7.5
Procedure Operative findings Pathologic findings
MVR, AVR No prolapse or chordal rupture “Stuck-on plaque” on leaflets
MVR, AVR, TV repair No chordal rupture or flail segment trileaflet AV “Stuck-on plaque” on leaflets
MVR Glistening white, thickened leaflets and chordae “Stuck-on plaque” on leaflets
MV repair Glistening white, thickened, tethered leaflets NA
MV repair Distinctly unusual—post. leaflet, thickened, tethered NA
Attempted repair, MVR Avulsion of central cusp of post. leaflet with ruptured White-gray glistening valve cusps, focally thickened 
chordae, elongated and torn ant. leaflet chordae chordae, consistent with myxoid valvulopathy
MVR, AVR Post. leaflet prolapse Focal myxoid changes
MVR, AVR Small post. leaflet, fused chordae, fixed ant. leaflet Thickened chordae
MV and AV repair Mitral annular dilatation NA 
MVR, AVR Thickened valve, thickened, tethered chordae Thickened leaflets and 
chordae
Attempted repair, MVR Thickening with retraction and scarring, chordae Glistening thickening of leaflets and chordae
primarily shortened, primary defect in mid-post. leaflet
MV repair Glistening white, thickened, tethered leaflets NA
Attempted, Thickening of chordae, malcoaptation of leaflets Mitral leaflet biopsy: normal mitral valve leaflet
repair, MVR
MVR Retraction of the post. leaflet with tethering and Mild focal leaflet and chordal thickening due to
shortened, fibrosed chordae focal surface proliferation; “stuck-on” appearance
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commissural fusion and stenosis. The anterior mitral leaflet
appeared thickened, with diastolic doming and retained
mobility. The posterior mitral leaflet tended to be thickened
with decreased mobility. The chordae tendineae were also
thickened and shortened and caused tethering of the poste-
rior leaflet; 1 patient also had chordal rupture. Echo-
cardiographic features of aortic valve involvement included
thickened and retracted valve cusps. Involved tricuspid
valves also demonstrated thickening with variable fixation
of the septal leaflet and decreased mobility of the anterior
leaflet (Figure 2). Left ventricular function was decreased in
only 1 patient (ejection fraction 40%).
All 14 patients underwent preoperative cardiac catheter-
ization. Results of coronary angiography were normal in 13
patients; 1 patient (40 years old) had 60% narrowing of the
ostium of the right coronary artery. Pulmonary hypertension
was found at cardiac catheterization in 6 patients (mean pul-
monary artery pressure 35.3 ± 10.6 mm Hg). Five of the 14
patients initially underwent a mitral valve repair, and of
these, 1 had concomitant aortic valve repair. At the time of
the initial operation in 2 patients, repair of the mitral valve
was attempted and then abandoned for prosthetic replace-
ment. Seven patients underwent mitral valve replacement as
an initial procedure, 5 with concomitant aortic valve
replacement. At operation, diseased valves were described
as having a glistening white appearance without the yellow-
ish discoloration or calcification that is often seen in
rheumatic heart disease (Figure 3). Valve leaflets and chor-
dae with the glistening white coating tended to have
decreased mobility because of both leaflet thickening and
TABLE 3.  Comparison of valvulopathies
Common positions Echocardiography
Rheumatic Mitral, aortic Thickened, hypomobile leaflets, MR, AR, AS
Ergot35 Mitral, aortic Thickened, hypomobile to nonmobile leaflets with variable stenosis
and regurgitation
Methysergide36,37 Aortic, mitral Thickened leaflets, MR 
Carcinoid38 Tricuspid, pulmonary Thickened leaflets with valvular stenosis and regurgitation, hypomobile 
or nonmobile leaflets with shortening of chordae
Diet drug Mitral, aortic, tricuspid Atypical for rheumatic, congenital, or degenerative lesions, thickening 
of leaflets and chordae, fixation of posterior MV leaflets, no obstruction
MR, Mitral regurgitation; AR, aortic regurgitation; AS, aortic stenosis; MV, mitral valve. 
Figure 2. Representative echocardiographic views of a mitral valve affected by anorexigen use. The left image
demonstrates the thickened valve leaflets, and the right shows severe mitral regurgitation. LV, Left ventricle; MV,
mitral valve.
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tethering by shortened chordae. As noted on the echocar-
diogram, 1 patient had chordal rupture. Microscopy demon-
strated characteristic plaque-like encasement of the leaflets
and chordal structures. The elastic–van Gieson stain demon-
strated smooth muscle cell hyperplasia in an abundant extra-
cellular matrix. This focal surface proliferation and fibrosis
was seen without evidence of inflammation or damage to
the underlying valve structure, giving the lesions a “stuck-
on” appearance (Figure 4).
There was no early or late mortality among the 14
patients in this series who underwent surgery. One patient
who initially underwent valve replacement elsewhere
required early reoperation for bleeding. Additionally, 2
years after valve repair, that same patient required valve
replacement for recurrent severe mitral regurgitation
(patient 13, Table 1). The 4 other patients who underwent
mitral valve repair are well 24 to 38 months after repair,
with no evidence of progression of valvular disease. All
patients who underwent valve replacement are well, now 12
to 36 months postoperatively.
Discussion
Fenfluramine was developed in 1962 by Beregi and associ-
ates,9 through a trifluromethyl substitution of amphetamine, in
an effort to produce a drug with the same anorectic effects but
with fewer stimulatory side effects than the parent compound.
In the central nervous system, fenfluramine causes the release
of serotonin10; however, it also has direct effects on metabo-
lism by increasing muscle glucose uptake11 and inhibiting
lipogenesis.12 The primary complication associated with the
Gross appearance Histology
White, thickened fibrotic valve leaflets, nodules, Dense fibrovascular, postinflammatory tissue,
calcifications, fused commissures Aschoff nodules, calcifications
White thickening and encasement of valve leaflets Proliferation of smooth-muscle cells and fibroblasts, 
and chordae avascular collagen matrix encasing leaflets and chordae, little 
destruction of normal underlying structures
Uniform glistening white thickening of leaflets and chordae, Avascular, poorly cellular fibrous tissue without elastic fibers,
fusion of commissures and chordae myocardial fibrosis
“Pearly white” thickening of leaflets and chordae Smooth-muscle cell proliferation without elastic fibers, plaques adherent
sometimes involving chambers to normal-appearing underlying structures
Glistening white leaflets and chordae with diffuse “Stuck-on” plaques, proliferative myelofibroblasts in an abundant
thickening, no calcifications, shortening of chordae with extracellular matrix
tethering of posterior MV leaflet
Figure 3. Photographs of valve excised from a patient exposed to fenfluramine and phentermine. Of note is the glis-
tening, pure-white appearance and thickening of the valve leaflets and chordae. Left, Viewed from the left atrium.
Right, Viewed from the left ventricle.
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use of fenfluramine has been pulmonary hypertension,13-15
although additional studies have also demonstrated that it may
be neurotoxic in monkeys.16,17 Fenfluramine was approved for
short-term treatment of obesity by the FDA in 1973 and has
since been prescribed for an estimated 70 million patients
worldwide for weight loss, with significant benefit compared
with placebo.18-23 The D-isomer of fenfluramine, dexfenflur-
amine, has many of the same anorectic properties as racemic
fenfluramine24-26; it too is associated with pulmonary hyper-
tension27,28 and neuronal toxicity.17
Phentermine is a sympathomimetic amine that acts by
interfering with central monoamine pathways through stim-
ulation of dopamine release and has an inhibitory role in the
metabolism of serotonin.29 It was approved for use in the
treatment of obesity by the FDA in 1959 and has been used
since as a single agent in the treatment of obesity.30,31
Phentermine, like other anorectics, has also been linked to
development of pulmonary hypertension.32
In 1984, Weintraub and associates6 found that the same
anorectic effects of fenfluramine and phentermine could be
achieved with half doses of each drug used in combination.
After this initial report, a clinical trial including 121
patients, who used the drugs for up to 3.5 years, confirmed
the efficacy of combination therapy.33 Prescribing fenflur-
amine and phentermine in combination for weight loss
became a common practice despite warnings such as that of
Atkinson and coauthors,34 who wrote, “With such a sparse
body of data in the literature, it is very hazardous to condone
the growing practice by private practitioners in the United
States of long term use of phentermine and fenfluramine.”
Anorexigen-associated valvular disease is similar patho-
logically to the valvulopathy seen with carcinoid syndrome.
This is not unexpected, however, since serotonin metabo-
lism is implicated in the pathophysiology of each condition.
Both carcinoid heart disease and anorexigen-associated
valvular disease share many similarities with ergot and
methysergide-induced valvulopathy. As seen in Table 3, the
features of drug-induced valvulopathy overlap but are easi-
ly distinguished from those of rheumatic heart disease. In
each of these conditions, patients may have symptoms of
dyspnea, palpitations, or heart failure related to severe
valvular regurgitation. Echocardiographic findings of leaflet
thickening and tethering by shortened chordae can suggest a
cause, but a detailed clinical history of diet drug use remains
the most important element in the diagnosis of anorexigen-
associated valvular disease.
Initial reports estimated that as many as one third of
patients who have used these diet medications may acquire
valvular disease; 2 recent studies suggest a lower incidence.
Khan and associates39 found that 22.7% of patients treated
with diet medications had valve abnormalities noted by
echocardiography, compared with 1.3% among controls. Jick
and coauthors40 found in their prospective case-controlled
study that the incidence of clinically detected valve disease
was only 35 per 10,000 patients who received fenfluramine or
dexfenfluramine for more than 4 months.
On the basis of this experience, several points regarding
surgical patients should be emphasized. First, even though
we recognize that many other patients having anorexigen-
induced valvulopathy have undergone surgery but were not
reported to us or the FDA, it is clear that severe valvular
regurgitation necessitating valve repair or replacement is
rare; millions of patients have been exposed to diet drugs,
but only a few will acquire valvular disease severe enough
to require surgery.
Second, the patient history is the most important feature
Figure 4. Photomicrographs of an excised valve from a patient with anorexigen-associated valvular disease. Left,
Mitral leaflet (hematoxylin and eosin stain; ×360). Right, High-power view of plaque (elastic–van Gieson stain;
×36). There is smooth muscle cell hyperplasia in an abundant extracellular matrix, without evidence of inflam-
mation or structural damage to the underlying structures. The plaques appear “stuck on.”
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leading to diagnosis. Patients with unexplained valvular
regurgitation should be queried regarding diet drug use,
ergot use for migraine headache, rheumatic fever, or symp-
toms of carcinoid disease. The clinician should have a high
index of suspicion in a previously healthy patient who pre-
sents with new symptoms of valve dysfunction and charac-
teristic echocardiographic features.
Third, patients exposed to anorexigens may have associ-
ated pulmonary hypertension that seems out of proportion to
the duration and severity of the mitral and aortic valvular
regurgitation. In this series, pulmonary hypertension did not
appear to affect early or late results of valve repair or
replacement, and pulmonary hypertension may improve
with discontinuation of medications and the repair or
replacement of diseased valves.
Fourth, at operation, the gross morphologic characteris-
tics of the valve may lead the surgeon to the correct diagno-
sis; the valves have a characteristic appearance and one that
can be distinguished from that in rheumatic heart disease. In
each of the included cases, the operative findings were sim-
ilar, with thickening of the valves and chordae, which had a
brilliant glistening white appearance. Histologic evaluation
of excised valves also demonstrated a consistent picture,
with smooth muscle proliferation in an abundant extracellu-
lar matrix, creating a “stuck on” appearance.
Fifth, in contrast to management of patients with carci-
noid heart disease, in which the involved tricuspid valve
exhibits variable degrees of stenosis mandating prosthetic
replacement, valve repair is an option for patients with
anorexigen-induced valvulopathy. In this study, patients
who underwent repair had the same characteristic tether-
ing of their posterior mitral leaflet and shortened chordae
as did patients who required valve replacement. However,
in the 4 patients who had a successful repair, the anterior
mitral leaflets were still quite mobile. Placement of a pos-
terior annuloplasty ring was sufficient to restore coapta-
tion of the leaflet in 3 patients. In 1 patient, incision of the
posterior medial papillary muscle, in addition to place-
ment of a posterior annuloplasty ring, allowed a greater
excursion of the posterior leaflet and restored coaptation.
One patient who initially underwent mitral valve repair
with the placement of an annuloplasty ring later required
valve replacement, but we do not know with certainty
whether this patient discontinued use of anorexigens or
whether the initial repair was completely satisfactory.
Because patients affected by this disease are primarily
young women, valve repair in this fashion, when possible,
seems preferable to valve replacement. Although valve
repair is advocated in select patients with preserved
mobility of leaflets, the severity of valvular disease in this
group required valve replacement in the majority of
patients (10/14). In only 4 patients was the degree of valve
thickening and chordal shortening limited enough to
allow repair. Although preservation of anterior leaflet
mobility was not the most common finding, in the situa-
tion in which it is preserved, valve repair has worked well. 
Finally, although the natural history of this disease is
not completely known, early anecdotal reports give no
indication that valvulopathy progresses once use of the
medications has been stopped; indeed, there may be
improvement in mild regurgitation over time.41
Additionally, we have had good results with mitral valve
repair performed for anorexigen-associated valvular dis-
ease at our institution, and we have not seen progression
of mitral valvulopathy on follow-up echocardiography.
In conclusion, it remains unclear how many patients will
eventually acquire severe valvulopathy from exposure to
anorexigens, but it is important for the cardiac surgeon to be
aware of this unique disease and to understand that valve
repair is a viable option for these young patients.
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